International Stem Cell Corporation (OTCBB: ISCO)
International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true “Stem Cell Bank” and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology.
Market Data
In the News
- International Stem Cell Corporation Announces Collaboration with Scripps Research Institute’s Center -
International Stem Cell Corporation (OTCBB: ISCO), announced today that it is collaborating with renowned stem cell researcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute (La Jolla, CA) to study parthenogenetic stem cells and potentially therapeutic cells that can be derived from them.
- ISCO.OB Announces Breakthrough In Creating Stem Cells -
International Stem Cell Corporation (OTCBB:ISCO) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived.
- International Stem Cell Corporation and Absorption Systems Announce Potential Stem Cell Alternative -
International Stem Cell Corporation (OTCBB:ISCO, www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with Absorption Systems to study ISCO’s stem-cell-derived human corneal tissue as an alternative to live animals for drug testing. Init
- International Stem Cell Corporation Issues Letter to Shareholders -
- International Stem Cell Corporation (OTCBB: ISCO) CEO and Chairman Kenneth Aldrich To Present Webcast at the Stem Cell Summit -
Tuesday May 12, 2009, 9:00-9:45 a.m. Pacific Time
Contact & RSS
Contacts 212.825.3210 |
Subscribe to International Stem Cell news, video, feature feeds, and more via RSS. |
FriendFeed